The validation cohort (TCGA) confirmed these results: the decile with the lowest <i>IL1A</i> expression had better overall survival (HR = 3.00 [1.14-7.90], <i>p</i> = 0.03) and a lower risk of progression (HR = 3.11 [1.24-7.80], <i>p</i> = 0.01).<h4>Conclusions</h4><i>IL1A</i> is an independent prognostic marker and could be considered a potential therapeutic target in pancreatic cancer patients. The gene discussed is IL1A; the disease is pancreatic neoplasm.